EWTX Edgewise Therapeutics Inc

Price (delayed)

$37.26

Market cap

$4.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.67

Enterprise value

$3.98B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 8

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. ...

Highlights
Edgewise Therapeutics's debt has decreased by 17% YoY and by 4.9% from the previous quarter
The quick ratio has grown by 14% from the previous quarter and by 7% YoY
Edgewise Therapeutics's equity has increased by 15% YoY but it has decreased by 6% from the previous quarter
The net income is down by 20% year-on-year and by 4.9% since the previous quarter
The EPS fell by 8% YoY and by 2.5% QoQ

Key stats

What are the main financial stats of EWTX

EWTX stock price

How has the Edgewise Therapeutics stock price performed over time
Intraday
2.9%
1 week
11.89%
1 month
18.47%
1 year
157.14%
YTD
50.15%
QTD
18.29%

Financial performance

How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$199.56M
Net income
-$176.01M
Gross margin
N/A
Net margin
N/A
The net income is down by 20% year-on-year and by 4.9% since the previous quarter
The operating income has declined by 17% year-on-year and by 4.3% since the previous quarter

Price vs fundamentals

How does EWTX's price correlate with its fundamentals

Growth

What is Edgewise Therapeutics's growth rate over time

Valuation

What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
8.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 8% YoY and by 2.5% QoQ
The P/B is 154% more than the 5-year quarterly average of 3.1 and 83% more than the last 4 quarters average of 4.3
Edgewise Therapeutics's equity has increased by 15% YoY but it has decreased by 6% from the previous quarter

Efficiency

How efficient is Edgewise Therapeutics business performance
EWTX's ROA is down by 5% year-on-year
EWTX's ROIC is down by 4.8% YoY
Edgewise Therapeutics's ROE has decreased by 5% YoY

Dividends

What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EWTX.

Financial health

How did Edgewise Therapeutics financials performed over time
Edgewise Therapeutics's total liabilities has decreased by 17% QoQ but it has increased by 2.6% YoY
The total assets has grown by 14% YoY but it has contracted by 6% from the previous quarter
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's debt has decreased by 17% YoY and by 4.9% from the previous quarter
Edgewise Therapeutics's equity has increased by 15% YoY but it has decreased by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.